Distributorship Agreement with iMAGINE-X Inc. for the “XCam-CdTe” X-ray and Gamma-ray Imaging System
Summit Pharmaceuticals International Corporation (head office: Chiyoda-ku, Tokyo; President: Katsuya Okuyama; hereinafter “SPI”) is pleased to announce that it has entered into a global, exclusive distributorship agreement with iMAGINE-X Inc. (head office: Shibuya-ku, Tokyo; President: Hokuto Inoue) regarding the sales of the company’s state-of-the-art X-ray and gamma-ray imaging system, “XCam-CdTe”.
SPI has formed a strategic partnership with iMAGINE-X, a company possessing innovative imaging technology, and will act as the exclusive distributor both in Japan and internationally.
The “XCam-CdTe” is a molecular imaging system equipped with iMAGINE-X’s proprietary double-sided CdTe (cadmium telluride) strip detector, offering world-class high resolution and sensitivity. By leveraging dedicated analog LSI and analytical algorithms to fully exploit the potential of the CdTe semiconductor, the system achieves more than twice the energy resolution* compared to conventional devices. This enables highly sensitive imaging based on efficient background noise suppression and precise multi-isotope imaging through accurate radionuclide identification. Furthermore, the integration of a high-efficiency pure tungsten collimator—produced using the latest metal 3D printing technology—allows for rapid photon collection required for imaging, making the system particularly effective in visualizing the in vivo dynamics of radiopharmaceuticals.
*Indicator of measurement precision for radiation energy
In recent years, demand has been growing for preclinical imaging of pharmacokinetics using therapeutic radionuclides, and the need for high-performance imaging technologies is rapidly increasing alongside the advancement of medical care. SPI has contributed to the progress of science and industrial technologies by introducing cutting-edge technologies from around the world into the Japanese market. Through this agreement, we will widely promote iMAGINE-X’s advanced technologies both domestically and globally, providing optimal solutions tailored to user needs.
Appearance of “XCam-CdTe”
(Image provided by Osaka University School of Medicine)
3 hours after 21 hours after
administration administration
Mice bearing tumors were administered a candidate radiopharmaceutical labeled with At-211 (Astatine-211), and imaged using XCam-CdTe. Even 21 hours after administration, when three half-lives had elapsed, the accumulation of the drug in the tumor, indicated by arrows, was clearly detected with high sensitivity.
【Company Profile – iMAGINE-X Inc.】
Address: ILA Shibuya Mitake Bldg. 505, 1-12-8 Shibuya, Shibuya-ku, Tokyo
Representative: Hokuto Inoue, President & CEO
Business Description: Development of high-resolution X-ray and gamma-ray imaging systems
Website: https://imagine-x.jp/
【Contact】
Summit Pharmaceuticals International Corporation
Research Promotion Dept., Bioscience Group
TEL: +81-3-5220-1520
Email: biosupport@summitpharma.co.jp
